InvestSMART

Biotron Limited (ASX: BIT) - Announcements

- Current share price for BIT : $0.002

ASX company news and announcements for Biotron Limited (BIT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Biotron Limited (BIT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Biotron Limited (BIT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Biotron Limited (BIT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Update on Phase 2 Trial and IND Progress 17 Apr 2015 10:18AM $0.125 $0.002 fallen by 98.40%
$6 Response to ASX price query 26 Feb 2015 12:48PM $0.150 $0.002 fallen by 98.67%
$6 Appendix 4C - quarterly 21 Jan 2015 4:12PM $0.120 $0.002 fallen by 98.33%
$6 Response to ASX Price Query 8 Jan 2015 9:40AM $0.125 $0.002 fallen by 98.40%
$6 Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed 3 Dec 2014 9:31AM $0.097 $0.002 fallen by 97.94%
$6 Appendix 4C - quarterly 31 Oct 2014 12:57PM $0.105 $0.002 fallen by 98.10%
$6 Rights Issue Prospectus 15 Oct 2014 9:56AM $0.125 $0.002 fallen by 98.40%
$6 Fully Underwritten Rights Issue and Investor Presentation 15 Oct 2014 9:55AM $0.125 $0.002 fallen by 98.40%
$6 Trading halt 13 Oct 2014 8:58AM $0.150 $0.002 fallen by 98.67%
$6 BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C 10 Oct 2014 9:42AM $0.165 $0.002 fallen by 98.79%
$6 Annual Report to Shareholders 28 Aug 2014 4:16PM $0.135 $0.002 fallen by 98.52%
$6 Appendix 4C - quarterly 24 Jul 2014 2:12PM $0.125 $0.002 fallen by 98.40%
$6 BIT225 Reverses HIV-Induced Impairment of the Immune System 23 Jul 2014 10:49AM $0.130 $0.002 fallen by 98.46%
$6 Response to ASX price query 6 Jun 2014 1:26PM $0.120 $0.002 fallen by 98.33%
$6 BIT225 HCV Trial Update - Thailand 23 May 2014 10:31AM $0.095 $0.002 fallen by 97.89%
$6 Appendix 4C - quarterly 24 Apr 2014 3:37PM $0.110 $0.002 fallen by 98.18%
$6 $1.7 Million R&D Tax Incentive Refund 4 Apr 2014 9:55AM $0.110 $0.002 fallen by 98.18%
$6 Update on BIT225 HCV Program 11 Mar 2014 11:58AM $0.145 $0.002 fallen by 98.62%
$6 BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS 6 Mar 2014 12:18PM $0.170 $0.002 fallen by 98.82%
$6 Half Yearly Report and Accounts 21 Feb 2014 11:01AM $0.081 $0.002 fallen by 97.53%
$6 Key USA Patent Allowed for Biotron's BIT225 13 Feb 2014 10:02AM $0.087 $0.002 fallen by 97.70%
$6 Response to ASX query 23 Jan 2014 12:18PM $0.090 $0.002 fallen by 97.78%
$6 Appendix 4C - quarterly 21 Jan 2014 10:57AM $0.092 $0.002 fallen by 97.83%
$6 Presentation of HIV Data at HIV Persistence Meeting 5 Dec 2013 9:38AM $0.083 $0.002 fallen by 97.59%
$6 Independent Research Validates Biotron HCV Drug Candidate 27 Nov 2013 10:18AM $0.087 $0.002 fallen by 97.70%

451 - 475 of 596 results

Page 19 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.